Congruence Therapeutics is a pioneering biotechnology company that operates at the forefront of drug discovery for rare diseases, particularly those stemming from protein misfolding. Founded in 2021 and headquartered in Montreal, Canada, the company distinguishes itself through its innovative, computationally-driven approach. Congruence leverages its proprietary platform, Revenir™, which integrates advanced fields such as protein dynamics, biophysics, machine learning, and computational chemistry. This powerful engine allows Congruence to move beyond traditional, static drug design by modeling the complex, dynamic nature of proteins, thereby identifying unique pockets and designing novel small molecules with the potential to correct aberrant protein function. The company's mission is to reinvent drug discovery to create transformative medicines for patients suffering from conditions with high unmet medical needs, including genetic obesity, GBA1-driven Parkinson's disease, and alpha-1 antitrypsin deficiency.